Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Deseret News Utah Index
Deseret News Composite
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Apellis Pharmaceuticals Inc
(NQ:
APLS
)
27.38
+0.24 (+0.88%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Apellis Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 04, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the UBS Virtual Ophthalmology Day
September 25, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Monday
September 23, 2024
Via
Benzinga
What's Going With Apellis Pharmaceuticals Stock Friday?
September 20, 2024
Apellis Pharmaceuticals shares are moving lower after the Committee for Medicinal Products for Human Use of the European Medicines Agency confirmed its June 2024 negative opinion following...
Via
Benzinga
Analyst Scoreboard: 15 Ratings For Apellis Pharmaceuticals
September 13, 2024
Via
Benzinga
Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know
August 02, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Apellis Pharmaceuticals Through Analyst Insights
July 17, 2024
Via
Benzinga
Apellis Stock Hammered After Eye Drug Gets A Third European Rejection
September 20, 2024
The company is "out of European approval options" for its embattled geographic atrophy drug, says one analyst.
Via
Investor's Business Daily
Apellis Receives Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU Following Re-Examination
September 20, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 06, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
August 29, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
What Analysts Are Saying About Apellis Pharmaceuticals Stock
June 28, 2024
Via
Benzinga
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts
May 28, 2024
Via
Benzinga
Wedbush Just Raised its Price Target on These 7 Stocks: August 12, 2024
August 13, 2024
New Wedbush price targets have been issued for each of the following seven stocks, including a few that may come as a surprise to some.
Via
InvestorPlace
Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
August 08, 2024
Swedish Orphan Biovitrum and Apellis Pharmaceuticals released topline results from the Phase 3 VALIANT study of pegcetacoplan for C3 glomerulopathy and IC-MPGN. The study met primary and secondary...
Via
Benzinga
Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN
August 08, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 06, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals
May 08, 2024
Via
Benzinga
Apellis Pharmaceuticals Reports Second Quarter 2024 Financial Results
August 01, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results
July 18, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting
July 09, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
June 28, 2024
Via
Benzinga
Apellis Plans to Seek Re-Examination Following Negative CHMP Opinion for Pegcetacoplan for Geographic Atrophy (GA) in the EU
June 28, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
SYFOVRE® (pegcetacoplan injection) Preserved Visual Function at 36 Months in GALE Extension Study in Geographic Atrophy (GA)
June 10, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare Conference
June 05, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress
May 24, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals Refinances Existing Debt with Up to $475 Million Non-Dilutive Credit Facility from Sixth Street
May 14, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
APLS Stock Earnings: Apellis Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024
May 07, 2024
APLS stock results show that Apellis Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Apellis Pharmaceuticals Reports First Quarter 2024 Financial Results
May 07, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
Apellis Pharmaceuticals to Host a Fireside Chat at the Bank of America Securities Healthcare Conference
May 06, 2024
From
Apellis Pharmaceuticals, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
...
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.